From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Agent | Base year | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
---|---|---|---|---|---|---|
Adalimumab | 30 | 27 | 25 | 24 | 23 | 23 |
Etanercept | 45 | 42 | 39 | 37 | 36 | 35 |
Infliximab | 25 | 22 | 20 | 18 | 17 | 16 |
Ustekinumab | 0 | 9 | 16 | 21 | 24 | 26 |